J William L Brown

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horáková et al. · JAMA · 2019 · 547 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He, B. Merkel, J William L Brown et al. · The Lancet Neurology · 2020 · 438 citations · Full text

Life Sciences, Neurology, Neuroscience +8

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 162 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

J William L Brown, Nick Cunniffe, Ferrán Prados et al. · The Lancet Neurology · 2021 · 95 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis

J William L Brown, Matteo Pardini, Wallace Brownlee et al. · Brain · 2016 · 79 citations · Full text

Medicine, Neurology, Neuroscience +17